论文部分内容阅读
PGF_(2a)及其甲基类似物15(S)15-甲基PGF_(2a)和15(S)15-甲基PGF_(2a)甲基酯用于598例妊娠9～20周的病人引产,采用不同的给药途径和剂量,其胃肠道副作用的发生率是在可接受的范围内。在羊膜内注射PGF_(2a)50毫克和15-甲基PGF_(2a)2.5毫克与肌肉内和阴道给予15-甲基PGF_(2a)或其甲基酯类疗效是一样的。到目前为止,已经静脉、羊膜内、羊膜外、肌肉和阴道给予PG用于不同妊娠期的引产,发现每一方法都有其优缺点。如一并考虑效能和副作用,羊膜内和阴道给药较好。此法给药方便,对终止妊娠有较广泛的适应范围。在许多情况下,重复阴道给予15-甲基PGF_(2a)甲基酯较好。
Methyl PGF_ (2a) and 15 (S) 15-Methyl PGF_ (2a) Methyl PGF_ (2a) and Its Methyl Analogues 15 (S) 15-Methyl PGF_ (2a) , The use of different routes of administration and dose, the incidence of gastrointestinal side effects are within acceptable range. The intramuscular and vaginal administration of 15-methyl PGF_ (2a) or its methyl esters was equally efficacious in amniotic injection of 50 mg of PGF_ (2a) and 2.5 mg of 15-methyl PGF_ (2a). To date, PG has been given intravenously, amnionally, intramnumatically, intramuscularly, and vaginally for induction of labor during different gestations and each method has its advantages and disadvantages. Taking into account the efficacy and side effects, amniotic membrane and vaginal administration is better. This method is convenient administration, termination of pregnancy have a wider range of adaptation. In many cases, it is better to administer 15-methyl PGF_ (2a) methyl ester vaginally.